Raptiva faces EU marketing suspension and US restrictions
This article was originally published in Scrip
Executive Summary
Genentech/Merck KGaA's psoriasis therapy Raptiva (efalizumab) faces marketing suspension in the EU and increased risk management measures in the US owing to its link with three confirmed cases of the brain infection, progressive multifocal leucoencephalopathy (PML).